ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer

被引：0
|
作者：
Kamath, Suneel
Tai, David
Moreno, Irene
Babiker, Hani
Jin, Zhaohui
Yoo, Changhoon
Ricard, Fabien
Jen, Kai Yu
Coward, Jim
Liu, Jia
Opdam, Frans
Millward, Michael
Ponz-Sarvise, Mariano
Yachnin, Jeffrey
Kim, Richard
Park, Joon Oh
Subbiah, Vivek
Schram, Alison M.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-24-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-24-01
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Bando, Hideaki
    Fukuoka, Shota
    Kojima, Takashi
    Naito, Yoichi
    Iino, Shuichi
    Yodo, Yasuhide
    Doi, Toshihiko
    Shitara, Kohei
    Yoshino, Takayuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 855 - 862
  • [22] Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
    Akihito Kawazoe
    Yasutoshi Kuboki
    Hideaki Bando
    Shota Fukuoka
    Takashi Kojima
    Yoichi Naito
    Shuichi Iino
    Yasuhide Yodo
    Toshihiko Doi
    Kohei Shitara
    Takayuki Yoshino
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 855 - 862
  • [23] 3HP-2827-high selective inhibitor of FGFR2, a best-in-class therapy for FGFR2-driven solid tumors
    Liu-Chen, Susan S.
    Lin, Jufang
    Hu, Jingyu
    Liu, Yanchao
    Zhang, Weibo
    Zhang, Zhixiong
    Ding, Yan
    Liu, Jinqiu
    Chen, Kevin
    Hu, Shaojing
    CANCER RESEARCH, 2024, 84 (06)
  • [24] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
    Guo, Ye
    Yuan, Chunwang
    Ying, Jieer
    Zhu, Xu
    Luan, Guodong
    Zhang, Bin
    Zhao, Renbin
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
    Xu, Jianming
    Cui, Jiuwei
    Jiang, Haiping
    Zeng, Yan
    Cong, Xiuyu
    CANCER MEDICINE, 2023, 12 (07): : 7762 - 7771
  • [27] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
    Li, Gary
    Krook, Melanie
    Roychowdhury, Sameek
    Avogadri, Francesca
    Ye, Yining
    Moran, Susan
    CANCER RESEARCH, 2019, 79 (13)
  • [28] A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors
    Shu, Pei
    Li, Xiaoyu
    Yuan, Li
    Zhou, Qi
    Li, Guiling
    Zhang, Keqiang
    Xie, Hui
    Wang, Yongsheng
    Li, Qiu
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort
    Yuan, Li
    Shu, Pei
    Li, Xiaoyu
    Li, Guiling
    Zhang, Keqiang
    Lai, Lin
    Hong, Jinsheng
    Huang, Chu-Ying
    Wang, Yongsheng
    Xie, Hui
    Zheng, Li
    Zhou, Qi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
    Rodon, J.
    Peltola, K.
    Azaro, A.
    Alvarez, E. Castanon
    Garratt, C.
    Leskinen, H.
    Bjorklund, H.
    Ruck, A.
    Massard, C.
    Bono, P.
    ANNALS OF ONCOLOGY, 2016, 27
12345